

B7 Sub C1

1. (Amended) A composition suitable for pharmaceutical, cosmetic or dermatological usage, said composition comprising:

- an amount of at least one agent sufficient to elicit an irritant side-effect to a user when utilized in a composition that does not include an interleukin-1 antagonist or a TNF-alpha antagonist, and wherein said irritant agent is an active agent in said composition,
- an amount of at least one compound selected from the group consisting of interleukin-1 antagonists, TNF-alpha antagonists and combinations thereof, sufficient to prevent or alleviate said irritant side-effect, and a cosmetically, dermatologically or pharmaceutically acceptable medium therefor, wherein the agent which produces the irritant side-effect is selected from the group consisting of alpha-keto acids, beta-keto acids, retinoids, anthralins, anthranoids, peroxides, minoxidil, lithium salts, antimetabolites, vitamin D and depigmentation agents.

B8 Sub C3

10. (Amended) A composition suitable for pharmaceutical, cosmetic or dermatological usage, said composition comprising

an amount of at least one agent sufficient to elicit an irritant side-effect to a user when utilized in a composition that does not include an interleukin-1 antagonist or a TNF-alpha antagonist, and wherein said irritant agent is an active agent in said composition;

B8  
Cont'd

at least one compound selected from the group consisting of interleukin-1 antagonists, TNF alpha antagonists and combinations thereof, in an amount effective to antagonize said irritant side-effect;

and a cosmetically, dermatologically or pharmaceutically acceptable medium therefor, said compound being capable of inhibiting the IL-1-induced adhesion of macrophages to endothelial cells, inhibiting the IL-1-induced release of superoxide anions from neutrophils, inhibiting the TNF alpha-induced adhesion of macrophages to endothelial cells, inhibiting the TNF alpha-induced release of superoxide anions from neutrophils, inhibiting the mitogenic activity of TNF alpha by dermal fibroblasts, or inhibiting the release of interleukin-1 or TNF alpha by phorbol ester induced differentiated monocytes, and wherein the agent which produces an irritant side-effect is selected from the group consisting of alpha-keto acids, beta-keto acids, retinoids, anthralins, anthranoids, peroxides, minoxidil, lithium salts, antimetabolites, vitamin D, and depigmentation agents.

Kindly add new claims 19, 20 and 21 as follows:

B9 Sub C

--19. (New) A composition suitable for pharmaceutical, cosmetic or dermatological usage, said composition comprising:

an amount of at least one agent sufficient to elicit an irritant side-effect to a user when utilized in a composition that does not include a TNF-alpha antagonist, and wherein said irritant agent is an active agent in said composition;

an amount of at least one TNF-alpha antagonist sufficient to prevent or alleviate said irritant side-effect; and

a cosmetically, dermatologically or pharmaceutically acceptable medium therefor wherein the agent which provides the irritant side-effect is selected from the group consisting of alpha-keto acids, beta-keto acids, retinoids, anthralins, anthranoids, peroxides, minoxidil, lithium salts, antimetabolites, vitamin D and depigmentation agents.

B9  
Cont

20. (New) A composition suitable for pharmaceutical, cosmetic or dermatological usage, said composition comprising:

an amount of at least one agent sufficient to elicit an irritant side-effect to a user when utilized in a composition that does not include an interleukin-1 antagonist or a TNF-alpha antagonist, and wherein said irritant agent is an active agent in said composition;

an amount of at least one interleukin-1 antagonist and at least one TNF-alpha antagonist, sufficient to prevent or alleviate said irritant side-effect; and

a cosmetically, dermatologically or pharmaceutically acceptable medium therefor.

21. (New) A composition suitable for pharmaceutical, cosmetic or dermatological usage, said composition comprising:

an amount of at least one agent sufficient to elicit an irritant side-effect to a user when utilized in a composition that does not include an interleukin-1 antagonist, and wherein said irritant agent is an active agent in said composition;

B9  
contd

an amount of at least one interleukin-1 antagonist, sufficient to prevent or alleviate said irritant side-effect; and

a cosmetically, dermatologically or pharmaceutically acceptable medium therefor, said agent being selected from the group consisting of alpha-keto acids, beta-keto acids, retinoids, anthralins, anthranoids, peroxides, minoxidil, lithium salts, antimetabolites, vitamin D and depigmentation agents.

---